Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 174 participants.
Also called NCT06290349
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 174 participants
- Sponsor
- Registry
-
NCT06290349
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06290349. Randomized; double masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2025-09-05 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- DA5221-T1
- Intervention (Drug)
- DA5221-T2
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- DA5221-B1
- Intervention (Drug)
- DA5221-B2
- Lead sponsor
- Dong-A ST Co., Ltd.
Record details
- Record id
cardio:ct-nct06290349- Content hash
0ba19b0143d2a57d821ebfc519f4461182a4efc43a275bae7a6f61d00fd6acf9